Toxicity and feasibility of total neoadjuvant therapy using short course radiation followed by chemotherapy

Heba H. Rashad; Hisham A. El Huseiny; Marwa M. Hussein; Reem M. Emad; Tarek M. El Baradei; Ahmad A. Abo Gabal; Yasser A. Abdelzim

doi:10.53730/ijhs.v6nS4.11835

Authors

Heba H. Rashad Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt
Hisham A. El Huseiny Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt
Marwa M. Hussein Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt
Reem M. Emad Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt
Tarek M. El Baradei Department of Surgical Oncology, National Cancer Institute, Cairo University, Egypt
Ahmad A. Abo Gabal Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt
Yasser A. Abdelzim
Yasser.anwar@nci.cu.edu.eg
Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt

Keywords:

total neoadjuvant, short course radiation, rectal cancer

Abstract

Introduction:Upfront neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy remained a standard of care for locally advanced rectal cancers. However this strategy is associated with high rates of distant failure. Total neoadjuvant therapy with short course radiation therapy (SCRT) followed by full course of chemotherapy is investigated to assess toxicity&feasibility. Patients and methods: Fifty-one patients with locally advanced rectal cancer who presented to the National Cancer Institute (NCI), Cairo University, in the period from March 2018 to December 2020 were enrolled. Patients were assigned to neoadjuvant short course radiation therapy (25 Gy/ 5 fractions/1 week), then 2 weeks from the end of radiation they were commenced to full course chemotherapy CAPOX (capecitabine1000 mg/m2 BID, D1-14 and oxaliplatin 130 mg/m2 D1) for 6 cycles, followed by surgery within 4-6 weeks from the last chemotherapy cycle. Type of surgery was decided upon surgeon’s discretion. Results: All patients completed their planned radiation therapy. Only 1 patient had grade III radiation related diarrhea. Forty three patients completed their planned chemotherapy course, 8 patients had grade III diarrhea. As regard hematological toxicity, 6 patients developed grade 3 toxicity and only one patient developed grade 4 toxicity.

Downloads

Download data is not yet available.

References

Amin MB, Greene FL, Edge SB et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017 Mar; 67(2):93-99.

Bahadoer RR, Dijkstra EA, van Etten B et al. RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan; 22(1):29-42.

Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114.

Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93:1215.

Erlandsson J, Holm T, Pettersson D et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017 Mar; 18(3):336-346.

Hatfield P, Hingorani M, Radhakrishna et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidit. Radiother Oncol 2009; 92: 210–214.

Jamuna, R. (2015). Data mining technique applied to DNA sequencing. International Research Journal of Management, IT and Social Sciences, 2(7), 15-19. Retrieved from https://sloap.org/journals/index.php/irjmis/article/view/314

Jing Jin, Yuan Tang, Chen Hu et al: A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports. JCO 2021 39:15_suppl, 3510-3510

Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001 Aug 30; 345(9):638-46.

Myerson RJ, Tan B, Hunt S, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):829-36.

Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012 Nov 1; 30(31):3827-33.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740.

Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30:1926-1933.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Suryatika, I. B. M., Anggarani, N. K. N., Poniman, S., & Sutapa, G. N. (2020). Potential risk of cancer in body organs as result of torak CT-scan exposure. International Journal of Physical Sciences and Engineering, 4(3), 1–6. https://doi.org/10.29332/ijpse.v4n3.465